165 related articles for article (PubMed ID: 32417565)
1. Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
Xie S; Ye L; Ye X; Lin G; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113353. PubMed ID: 32417565
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
3. Development of UPLC-MS/MS method for studying the pharmacokinetic interactions of pexidartinib with antifungal drugs in rats.
Shi L; Jiang Z; Zhang B; Tang C; Xu RA
J Pharm Biomed Anal; 2020 Sep; 188():113386. PubMed ID: 32502954
[TBL] [Abstract][Full Text] [Related]
4. Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum.
Müller C; Gehlen D; Blaich C; Prozeller D; Liss B; Streichert T; Wiesen MHJ
Ther Drug Monit; 2017 Oct; 39(5):505-513. PubMed ID: 28742650
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
6. An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study.
Wang Q; Chen Z; Chen D; Ye XY
Drug Des Devel Ther; 2020; 14():2061-2067. PubMed ID: 32546970
[TBL] [Abstract][Full Text] [Related]
7. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
Dai D; Yang H; Nabhan S; Liu H; Hickman D; Liu G; Zacher J; Vutikullird A; Prakash C; Agresta S; Bowden C; Fan B
Eur J Clin Pharmacol; 2019 Aug; 75(8):1099-1108. PubMed ID: 31011758
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study.
Dittakavi S; Jat RK; Mullangi R
Drug Res (Stuttg); 2019 Sep; 69(9):505-511. PubMed ID: 30822797
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
Shao Y; Xie S; Zhu H; Du X; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113355. PubMed ID: 32442869
[TBL] [Abstract][Full Text] [Related]
10. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.
Lou Y; Song F; Cheng M; Hu Y; Chai Y; Hu Q; Wang Q; Zhou H; Bao M; Gu J; Zhang Y
PeerJ; 2023; 11():e15844. PubMed ID: 37581117
[TBL] [Abstract][Full Text] [Related]
11.
Tang C; Niu X; Shi L; Zhu H; Lin G; Xu RA
Front Pharmacol; 2020; 11():626897. PubMed ID: 33613287
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
[TBL] [Abstract][Full Text] [Related]
13. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma.
Xiong X; Zhai S; Duan J
Clin Chem Lab Med; 2013 Feb; 51(2):339-46. PubMed ID: 23095205
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay.
Zhang Y; Liu YN; Xie S; Xu X; Xu RA
Pharm Biol; 2022 Dec; 60(1):621-626. PubMed ID: 35289238
[TBL] [Abstract][Full Text] [Related]
15. A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum.
Basu SS; Petrides A; Mason DS; Jarolim P
Clin Chem Lab Med; 2017 May; 55(6):836-844. PubMed ID: 27866173
[TBL] [Abstract][Full Text] [Related]
16. Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC-MS/MS.
Fu Y; Li Y; Ma Y; He X; Xun X; Cui Y; Fan L; Dong Z
Biomed Chromatogr; 2023 Jan; 37(1):e5525. PubMed ID: 36241418
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats.
Chen M; Zhang X; Chen Y; Sun W; Wang Z; Huang C; Hu G; Chen R
Xenobiotica; 2020 Mar; 50(3):280-287. PubMed ID: 31199171
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
19. Potential interactions between triazole antifungal agents and lorlatinib based on ultra-performance liquid chromatography-tandem mass spectrometry in rat plasma.
Ye Z; Wang C; Li R; Chen C; Yang J; Chen Y; Fu J; Zhou T; Jin M; Huang A; Zhang X; Zhou Z
J Pharm Pharmacol; 2024 Jan; 76(2):115-121. PubMed ID: 38150242
[TBL] [Abstract][Full Text] [Related]
20. Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Luo X; Xue X; Li T; Zhang Y; Huang L; Cheng G
Curr Drug Metab; 2020; 21(13):1022-1030. PubMed ID: 33092505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
